AstraZeneca and HKSTP Expand Collaboration with MoU to Support Start-Ups
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) and Hong Kong Science and Technology Parks Corp....
CStone Pharmaceuticals’ Sugemalimab Files for New Indication with NMPA for Esophageal Cancer
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) has...
Biosion Receives FDA Approval for Phase II Study of TSLP mAb BSI-045B
Global, clinical-stage biotech company Biosion, dedicated to developing antibody-based therapies for immune and oncologic diseases,...
Shanghai Best-Link Bioscience Secures $29 Million in Series A Financing for Nano Drug Innovation
Shanghai Best-Link Bioscience, LLC, a leading nano drug and drug delivery-focused enterprise based in Shanghai,...
OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial
US-based OncoSec Medical Inc., (OTCMKTS: ONCSQ), majority-owned by China-based Grand Pharmaceutical Group Ltd (HKG: 0512),...
Legend Biotech Corporation Appoints Industry Veterans to Strategic Advisory Board
China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced the formation of a strategic advisory board...
Beijing-Tianjin-Hebei Alliance Completes VBP Tender for Coronary Intervention Devices with 78.29% Price Cut
The Beijing-Tianjin-Hebei “3+N” allied region has completed a volume-based procurement (VBP) tender for coronary catheters,...
Jacobio Pharma Receives Approval for Phase I/IIa Study of LIF mAb in Advanced Solid Tumors
China-based Jacobio Pharma (HKG: 1167) has announced receiving approval in China to conduct a Phase...
Nanjing Zenshine Pharmaceuticals’ ZX-7101A Meets Primary Endpoint in Phase II Influenza Study
China-based small molecule drug developer Nanjing Zenshine Pharmaceuticals Co., Ltd announced that a Phase II...
WuXi Advanced Therapies (WuXi ATU) Closes Manufacturing Facilities in Shanghai Due to Market Changes
Media reports indicate that WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused Contract...
Shenzhen Hepalink’s Subsidiary Techdow USA Secures Distribution Rights for ANDA-Approved Drug
China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399) has announced that its wholly owned...
SPH CanSinoBio Suspends COVID-19 Vaccine Production for 180 Days Amid Market Shifts
SPH CanSinoBio, a joint venture between Shanghai Pharmaceuticals Group (SHA: 601607, HKG: 2607) and CanSino...
CNBG and Sinopharm Form Partnership to Integrate Medical Industries
China National Biotec Group Company Ltd (CNBG) has announced a strategic partnership with its parent...
Beijing’s Surgerii Secures Series C3 Financing to Advance Endoscopic Surgical Robot Technology
Beijing-based endoscopic surgical robot developer, Beijing Surgerii Robotics Company Limited, has reportedly raised hundreds of...
Lynk Pharmaceuticals Concludes Phase I Study for JAK Inhibitor LNK01003 with Positive Results
China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd has announced the successful conclusion of a Phase I...
BioNTech and Duality Biologics Ink Exclusive License Agreement for ADC Assets
Germany-based BioNTech SE (NASDAQ: BNTX) and China-headquartered Duality Biologics (Suzhou) Co., Ltd have announced that...
China’s Life Expectancy on Track to Surpass 81.3 Years by 2035, Study Reveals
A recent study published in The Lancet has provided updated forecasts for life expectancy in...
Willingmed Secures Series B Funding to Advance Clinical Infection Diagnostics
Willingmed, a Beijing-based company specializing in molecular biology for clinical infection precision diagnosis, has reportedly...
CDE Launches Guidelines to Expedite Pediatric and Rare Disease Drug Reviews
The Center for Drug Evaluation (CDE) has unveiled a new set of “Work Specifications to...
Johnson & Johnson’s Talquetamab on Track for Breakthrough Therapy Designation in Multiple Myeloma
China’s Center for Drug Evaluation (CDE) has indicated that US pharmaceutical giant Johnson & Johnson’s...